- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- TA
- ID number:
- 6128
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 February 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 November 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in early December 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late February 2024. |
For further information on how we select topics for development, please see our page about prioritising our guidance topics